Theravance Biopharma Crecimiento futuro

Future controles de criterios 4/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Theravance Biopharma de 63.8% y 24.4% respectivamente, mientras que el BPA crecerá en un 63.7% al año.

Información clave

57.2%

Tasa de crecimiento de los beneficios

57.4%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	23.7%
Tasa de crecimiento de los ingresos	18.9%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	06 Aug 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

We're Interested To See How Theravance Biopharma (NASDAQ:TBPH) Uses Its Cash Hoard To Grow

Jul 16

Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

May 02

Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Feb 05

Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Nov 11

Theravance to purchase $95M of ordinary shares

Sep 28

Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Sep 21

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Aug 09

Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study

Jun 21

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

May 09

Theravance Biopharma EPS misses by $0.16, misses on revenue

May 04

Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why

Apr 21

Previsiones de crecimiento de beneficios e ingresos

NasdaqGM:TBPH - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	118	17	108	48	5
12/31/2025	96	3	5	9	5
12/31/2024	71	-36	-12	-14	5
6/30/2024	62	-46	-10	-9	N/A
3/31/2024	62	-45	-18	-17	N/A
12/31/2023	57	-55	-29	-27	N/A
9/30/2023	55	-61	-152	-150	N/A
6/30/2023	51	-68	-172	-170	N/A
3/31/2023	49	-75	-173	-172	N/A
12/31/2022	51	-93	-188	-187	N/A
9/30/2022	52	-136	-106	-105	N/A
6/30/2022	52	-196	-131	-129	N/A
3/31/2022	54	-226	-166	-164	N/A
12/31/2021	55	-265	-211	-208	N/A
9/30/2021	59	-266	-235	-230	N/A
6/30/2021	64	-264	-267	-262	N/A
3/31/2021	66	-275	-273	-265	N/A
12/31/2020	72	-295	-257	-250	N/A
9/30/2020	83	-285	-257	-250	N/A
6/30/2020	77	-270	-222	-217	N/A
3/31/2020	88	-247	-215	-212	N/A
12/31/2019	73	-236	-241	-238	N/A
9/30/2019	60	-221	-229	-226	N/A
6/30/2019	60	-222	-236	-230	N/A
3/31/2019	57	-223	-250	-244	N/A
12/31/2018	60	-216	-120	-113	N/A
9/30/2018	49	-252	-111	-105	N/A
6/30/2018	41	-260	-123	-118	N/A
3/31/2018	21	-285	N/A	-101	N/A
12/31/2017	15	-285	N/A	-201	N/A
9/30/2017	17	-266	N/A	-185	N/A
6/30/2017	31	-233	N/A	-135	N/A
3/31/2017	33	-214	N/A	-123	N/A
12/31/2016	49	-191	N/A	-99	N/A
9/30/2016	47	-168	N/A	-105	N/A
6/30/2016	38	-182	N/A	-124	N/A
3/31/2016	40	-182	N/A	-139	N/A
12/31/2015	42	-182	N/A	-169	N/A
9/30/2015	40	-202	N/A	-178	N/A
6/30/2015	35	-209	N/A	-182	N/A
3/31/2015	31	-219	N/A	-187	N/A
12/31/2014	12	-237	N/A	-175	N/A
9/30/2014	10	-217	N/A	-168	N/A
6/30/2014	4	-203	N/A	-164	N/A
3/31/2014	1	-184	N/A	-137	N/A
12/31/2013	0	-156	N/A	-121	N/A
9/30/2013	5	-141	N/A	-108	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que TBPH sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2.4%).

Beneficios vs. Mercado: Se prevé que TBPH sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que TBPH sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (24.4% al año) de TBPH crezcan más rápidamente que los del mercado US (8.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 18.9% al año) de TBPH crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de TBPH se prevé que sea elevada dentro de 3 años.

Theravance Biopharma Crecimiento futuro

Future controles de criterios 4/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus revenue estimates increase by 12%

Forecast breakeven date moved forward to 2025

Price target increased by 12% to US$15.40

Consensus EPS estimates fall by 33%

Price target decreased by 10% to US$13.00

Forecast to breakeven in 2026

Recent updates

Theravance Biopharma, Inc. to Report Q2, 2024 Results on Aug 05, 2024

We're Interested To See How Theravance Biopharma (NASDAQ:TBPH) Uses Its Cash Hoard To Grow

Consensus revenue estimates increase by 12%

Forecast breakeven date moved forward to 2025

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Shareholders May Be More Conservative With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation For Now

Theravance Biopharma, Inc. to Report Q1, 2024 Results on May 13, 2024

Price target increased by 12% to US$15.40

Consensus EPS estimates fall by 33%

Full year 2023 earnings: EPS misses analyst expectations

Theravance Biopharma, Inc. to Report Q4, 2023 Results on Feb 26, 2024

New major risk - Financial position

Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Price target decreased by 10% to US$13.00

Theravance Biopharma Announces Results from the Phase 4 YUPELRI®? PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Forecast to breakeven in 2026

Theravance Biopharma, Inc. Appoints Jeremy Grant as Independent Director

Theravance Biopharma, Inc. Announces Board Changes

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Theravance Biopharma, Inc., Annual General Meeting, May 08, 2024

Theravance Biopharma, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders

New minor risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Theravance Biopharma, Inc. to Report Q2, 2023 Results on Aug 07, 2023

First quarter 2023 earnings released: US$0.35 loss per share (vs US$0.34 loss in 1Q 2022)

Forecast to breakeven in 2024

Price target increased by 12% to US$14.00

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased by 7.9% to US$12.47

Consensus EPS estimates fall by 19%

No longer forecast to breakeven

Chairman & CEO recently sold US$560k worth of stock

Theravance Biopharma, Inc. Announces Chief Financial Officer Changes

Insider notifies of intention to sell stock

Price target increased to US$11.62

Insufficient new directors

Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to US$11.57

Theravance Biopharma, Inc. Presents New Ampreloxetine Data in Neurogenic Orthostatic Hypotension

Theravance Biopharma, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Theravance Biopharma, Inc. (NasdaqGM:TBPH) announces an Equity Buyback for $60 million worth of its shares.

Theravance to purchase $95M of ordinary shares

Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Theravance Biopharma, Inc. (NasdaqGM:TBPH) announces an Equity Buyback for $250 million worth of its shares.

Consensus forecasts updated

Theravance Biopharma, Inc. (NasdaqGM:TBPH) announces an Equity Buyback for $250 million worth of its shares.

Theravance Biopharma announces $250M capital return program

Consensus forecasts updated

Insider recently sold US$133k worth of stock

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.80 loss in 2Q 2021)

Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M

Theravance Biopharma, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 85% stake in Theravance Respiratory Company, LLC.

Forecast breakeven date pushed back to 2023

Royalty Pharma plc (NasdaqGS:RPRX) entered into a definitive agreement to acquire unknown stake in Theravance Respiratory Company, LLC for $1.4 billion.

Royalty Pharma plc (NasdaqGS:RPRX) entered into a definitive agreement to acquire unknown stake in Theravance Respiratory Company, LLC for $1.4 billion.

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Theravance Biopharma, Inc. to Report Q1, 2022 Results on May 05, 2022

Insufficient new directors

Theravance Biopharma, Inc. Announces Results from Study 0170

Theravance: All-Round Failure

Price target increased to US$10.86

Full year 2021 earnings: EPS and revenues miss analyst expectations

Theravance Biopharma, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Consensus forecasts updated

Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study